2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations
暂无分享,去创建一个
W. Almahmeed | U. Baber | Q. Nguyen | D. Duplyakov | C. Chin | D. Chew | Ya‐Ling Han | Byeong‐Keuk Kim | Yi Li | J. Tan | A. Fong | J. Al Suwaidi | D. Firman | B. Karadağ | G. Steg | J. Ako | J. Dalal | W. Buddhari | H. Gamra | K. Tsui | A. Shehab | P. Ong | Zulu Wang | D. Tan | A. Hammoudeh | M. Sobhy | M. Chan | Bo Zhang | L. Tam | K. Xu
[1] Samin K. Sharma,et al. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. , 2021, European heart journal.
[2] M. Jeong,et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial , 2021, The Lancet.
[3] Yong Hwan Park,et al. P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor , 2021, Heart.
[4] S. Rhie,et al. P2Y12 Antiplatelet Choice for Patients with Chronic Kidney Disease and Acute Coronary Syndrome: A Systematic Review and Meta-Analysis , 2021, Journal of personalized medicine.
[5] Q. Nguyen,et al. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome , 2021, European cardiology.
[6] W. Almahmeed,et al. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region , 2021, European cardiology.
[7] Yong Hwan Park,et al. Safety of 3‐Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus‐Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART‐CHOICE Trial , 2020, Journal of the American Heart Association.
[8] B. Lindahl,et al. Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome , 2020, Circulation.
[9] Deepak L. Bhatt,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.
[10] Y. Kim,et al. Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent implantation in dialysis patients , 2020, Clinical kidney journal.
[11] M. Voskuil,et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial , 2020, The Lancet.
[12] P. Serruys,et al. Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention , 2020, Circulation. Cardiovascular interventions.
[13] Marco Valgimigli,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.
[14] P. Serruys,et al. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial , 2020, Clinical Research in Cardiology.
[15] P. Serruys,et al. Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[16] Y. Song,et al. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention-Reply. , 2019, JAMA.
[17] Samin K. Sharma,et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.
[18] S. Volpato,et al. Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study , 2019, Cardiovascular Drugs and Therapy.
[19] J. Zamorano,et al. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry , 2019, European heart journal.
[20] Deepak L. Bhatt,et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. , 2019, The New England journal of medicine.
[21] Deepak L. Bhatt,et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. , 2019, Lancet.
[22] H. Okayama,et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. , 2019, JAMA.
[23] Yong Hwan Park,et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. , 2019, JAMA.
[24] L. Køber,et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. , 2019, European heart journal.
[25] S. de Servi,et al. Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes , 2019, Journal of geriatric cardiology : JGC.
[26] Deepak L. Bhatt,et al. Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs , 2018, Thrombosis and Haemostasis.
[27] R. Charnigo,et al. Higher Risk of Bleeding in Asians Presenting With ST-Segment Elevation Myocardial Infarction: Analysis of the National Inpatient Sample Database , 2018, Angiology.
[28] D. Angiolillo,et al. Diabetes and antiplatelet therapy: from bench to bedside. , 2018, Cardiovascular diagnosis and therapy.
[29] Yong Hwan Park,et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial , 2018, The Lancet.
[30] S. Pocock,et al. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients) , 2018, Circulation. Cardiovascular interventions.
[31] T. Park,et al. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug‐eluting stents (SMART‐CHOICE): A prospective multicenter randomized trial , 2018, American heart journal.
[32] S. Cook,et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial , 2018, The Lancet.
[33] Qing Zhang,et al. Comparison of coronary artery bypass grafting and drug-eluting stents in patients with chronic kidney disease and multivessel disease: A meta-analysis. , 2017, European journal of internal medicine.
[34] P. Rothwell,et al. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study , 2017, The Lancet.
[35] Deepak L. Bhatt,et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials , 2017, The Lancet.
[36] Spiros C. Denaxas,et al. Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors , 2017, European heart journal.
[37] S. Kuo,et al. Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[38] Ran Liu,et al. Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding scores in ACS patients undergoing PCI: insights from a cohort of 4939 patients in China , 2017, Journal of geriatric cardiology : JGC.
[39] S. Bangalore,et al. Management and outcomes of acute myocardial infarction in patients with chronic kidney disease. , 2017, International journal of cardiology.
[40] S. Pocock,et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. , 2016, American heart journal.
[41] P. Serruys,et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[42] Y. Khader,et al. Cardiovascular risk factors in Middle Eastern patients undergoing percutaneous coronary intervention: Results from the first Jordanian percutaneous coronary intervention study , 2016, Journal of the Saudi Heart Association.
[43] S. Pocock,et al. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. , 2016, Journal of the American College of Cardiology.
[44] J. Spertus,et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.
[45] N. Kleiman,et al. Detection and quantification of circulating immature platelets: agreement between flow cytometric and automated detection , 2016, Journal of Thrombosis and Thrombolysis.
[46] H. Suryapranata,et al. Advanced age and high‐residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor , 2016, Journal of thrombosis and haemostasis : JTH.
[47] E. Hannan,et al. Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. , 2015, Journal of the American College of Cardiology.
[48] S. Windecker,et al. Stable coronary artery disease: revascularisation and invasive strategies , 2015, The Lancet.
[49] Peter L Duffy,et al. Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Registry , 2015, Circulation. Cardiovascular interventions.
[50] Marc P. Bonaca,et al. Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.
[51] Mandeep Singh,et al. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry. , 2013, JACC. Cardiovascular interventions.
[52] T. Lindahl,et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. , 2013, Journal of the American College of Cardiology.
[53] M. Woodward,et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.
[54] D. Chew,et al. The impact of increased age on outcome from a strategy of early invasive management and revascularisation in patients with acute coronary syndromes: retrospective analysis study from the ACACIA registry , 2012, BMJ Open.
[55] G. Stone,et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. , 2011, JACC. Cardiovascular interventions.
[56] K. Sangkuhl,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy , 2011, Clinical pharmacology and therapeutics.
[57] K. Alexander,et al. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. , 2011, The American journal of cardiology.
[58] Howard Balshem,et al. GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.
[59] A. M. Fager,et al. Properties of Procoagulant Platelets: Defining and Characterizing the Subpopulation Binding a Functional Prothrombinase* , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[60] The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.
[61] S. Pocock,et al. A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.
[62] Deepak L. Bhatt,et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis , 2010, European heart journal.
[63] S. Pocock,et al. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. , 2009, JACC. Cardiovascular interventions.
[64] Sunil V. Rao,et al. Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score , 2009, Circulation.
[65] Deepak L. Bhatt,et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.
[66] G. Remuzzi,et al. Platelet dysfunction in renal failure. , 2004, Seminars in thrombosis and hemostasis.
[67] Deepak L. Bhatt,et al. Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery , 2001, Circulation.
[68] S. Mezzano,et al. Hemostatic Disorder of Uremia: The Platelet Defect, Main Determinant of the Prolonged Bleeding Time, Is Correlated with Indices of Activation of Coagulation and Fibrinolysis , 1996, Thrombosis and Haemostasis.
[69] G. Zilleruelo,et al. In Vitro and In Vivo Evaluation of the Comparative Thrombogenicity of Cellulose Acetate Hemodialyzers with Radiolabeled Platelets , 1994, ASAIO journal.
[70] G. Remuzzi,et al. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. , 1983, The Journal of clinical investigation.
[71] C. Li,et al. Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease , 2018, British journal of clinical pharmacology.
[72] P. Kolh,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[73] M. Pencina,et al. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. , 2009, JACC. Cardiovascular interventions.
[74] C. Folman,et al. Plasma thrombopoietin levels in patients with chronic renal failure. , 2002, The hematology journal : the official journal of the European Haematology Association.
[75] H. Bessler,et al. Platelet count and thrombopoietic activity in patients with chronic renal failure. , 1987, Nephron.
[76] K. Menon. Twilight in China , 1972 .